Literature DB >> 6902725

Degradation of fibronectin by human leukocyte elastase. Release of biologically active fragments.

J A McDonald, D G Kelley.   

Abstract

We have identified the biological activity of three polypeptides released by limited proteolysis of human plasma fibronectin by leukocyte elastase. A Mr = 140,000 peptide contains cell-spreading activity; a Mr = 60,000 peptide mediates binding to denatured collagen (gelatin), and a Mr = 29,000 peptide contains glutaminyl residues responsible for the transglutaminase (blood coagulation factor XIIIa)-catalyzed incorporation of amines. More extensive proteolysis yielded numerous peptides, including a Mr = 40,000 peptide derived from the Mr = 60,000 peptide which retains gelatin-binding activity. Quantification of the gelatin-binding peptides is consistent with two binding sites per dimeric fibronectin molecule of Mr = 440,000. Both Mr = 60,000 and 40,000 gelatin-binding peptides were enriched with half-cystine residues, containing 28 and 25, respectively, but devoid of cysteine. This, coupled with the electrophoretic behavior of both peptides, was consistent with the presence of intramolecular disulfide bonds in the gelatin-binding domain. Intact fibronectin contains 1 free cysteine residue/monomer, as recently described. This cysteine reacts with 5,5'-dithiobis(2-nitrobenzoic acid) very slowly under nondenaturing conditions but rapidly when fibronectin is denatured. The free cysteine is located in the Mr = 140,000 peptide. While the Mr = 40,000 and 60,000 gelatin-binding peptides bind to gelatin with an affinity about 30-fold and 5-fold less than intact fibronectin (based on a monomeric fibronectin Mr = 220,000), neither gelatin-binding peptide supports spreading of fibronectin-deficient test cells on gelatin or tissue culture plastic substrates. The purified Mr = 140,000 peptide supported cell spreading on plastic, retaining about one-half of the spreading activity of intact fibronectin on a weight basis. These data confirm recent results, suggesting multiple, protease- resistant domains with discrete biological functions within fibronectin. Our results, together with established data, suggest a model for the location of the transglutaminase-reactive glutaminyl residues, gelatin binding, and cell-adhesive domains in fibronectin. The release of univalent, biologically active fibronectin fragments by elastase, a major physiologically released inflammatory protease of human leukocytes, suggests a new potential mechanism for alteration of cell connective tissue interactions at sites of inflammation in vivo.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6902725

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

1.  Differential effects of substrate modulus on human vascular endothelial, smooth muscle, and fibroblastic cells.

Authors:  Karyn G Robinson; Ting Nie; Aaron D Baldwin; Elaine C Yang; Kristi L Kiick; Robert E Akins
Journal:  J Biomed Mater Res A       Date:  2012-02-28       Impact factor: 4.396

2.  Identification with monoclonal antibodies of different regions of human plasma fibronectin, including that which interacts with human monocyte fibronectin receptors.

Authors:  J K Czop; J L Kadish; D M Zepf; K F Austen
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

3.  Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells.

Authors:  J P Quigley; L I Gold; R Schwimmer; L M Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

4.  Degradation of protease inhibitors, immunoglobulins, and other serum proteins by Serratia protease and its toxicity to fibroblast in culture.

Authors:  A Molla; K Matsumoto; I Oyamada; T Katsuki; H Maeda
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

5.  Cathepsin G and elastase in synovial fluid and peripheral blood in reactive and rheumatoid arthritis.

Authors:  D Nordstrom; O Lindy; Y T Konttinen; A Lauhio; T Sorsa; C Friman; T Pettersson; S Santavirta
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

6.  Fibronectin in the synovium of chronic inflammatory joint disease.

Authors:  V Mayston; P I Mapp; P G Davies; P A Revell
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

7.  The inhibitory effects of antirheumatic drugs on the activity of human leukocyte elastase and cathepsin G.

Authors:  J Steinmeyer; D A Kalbhen
Journal:  Inflamm Res       Date:  1996-07       Impact factor: 4.575

8.  Binding of fibronectin to the surface of group A, C, and G streptococci isolated from human infections.

Authors:  L M Switalski; A Ljungh; C Rydén; K Rubin; M Höök; T Wadström
Journal:  Eur J Clin Microbiol       Date:  1982-12       Impact factor: 3.267

9.  Fibronectin--mediator between cells and connective tissue.

Authors:  H Hörmann
Journal:  Klin Wochenschr       Date:  1982-10-15

10.  Elastase of U-937 monocytelike cells. Comparisons with elastases derived from human monocytes and neutrophils and murine macrophagelike cells.

Authors:  R M Senior; E J Campbell; J A Landis; F R Cox; C Kuhn; H S Koren
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.